WooGene B&G Co. Ltd (018620) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.015x

Based on the latest financial reports, WooGene B&G Co. Ltd (018620) has a cash flow conversion efficiency ratio of 0.015x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩987.57 Million ≈ $669.26K USD) by net assets (₩66.90 Billion ≈ $45.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see WooGene B&G Co. Ltd (018620) market capitalisation for the company's overall valuation and market capitalisation.

WooGene B&G Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how WooGene B&G Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

WooGene B&G Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of WooGene B&G Co. Ltd ranked by their cash flow conversion efficiency. Explore WooGene B&G Co. Ltd (018620) cash flow quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Sam Jung Pulp KO:009770	0.001x
Cs Holdings KO:000590	0.007x
City Sports and Recreation Public Company Limited BK:CSR	0.010x
Asian Phytoceuticals Public Company Limited BK:APCO	0.029x
Workpoint Entertainment Public Company Limited BK:WORK	0.000x
Genie Music Corporation KQ:043610	0.050x
Tadmax Resources Berhad KLSE:4022	-0.067x
CTI Traffic Industries Co Ltd TWO:2230	-0.134x

Annual Cash Flow Conversion Efficiency for WooGene B&G Co. Ltd (2011–2024)

The table below shows the annual cash flow conversion efficiency of WooGene B&G Co. Ltd from 2011 to 2024. View WooGene B&G Co. Ltd stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩27.79 Billion ≈ $18.83 Million	₩6.78 Billion ≈ $4.60 Million	0.244x	+540.75%
2023-12-31	₩72.33 Billion ≈ $49.02 Million	₩2.76 Billion ≈ $1.87 Million	0.038x	-47.68%
2022-12-31	₩35.32 Billion ≈ $23.93 Million	₩2.57 Billion ≈ $1.74 Million	0.073x	-44.60%
2021-12-31	₩31.14 Billion ≈ $21.11 Million	₩4.09 Billion ≈ $2.77 Million	0.131x	+58.90%
2020-12-31	₩29.85 Billion ≈ $20.23 Million	₩2.47 Billion ≈ $1.67 Million	0.083x	+221.95%
2019-12-31	₩27.27 Billion ≈ $18.48 Million	₩-1.85 Billion ≈ $-1.25 Million	-0.068x	+51.68%
2018-12-31	₩26.51 Billion ≈ $17.97 Million	₩-3.72 Billion ≈ $-2.52 Million	-0.140x	-110.00%
2017-12-31	₩23.04 Billion ≈ $15.61 Million	₩-1.54 Billion ≈ $-1.04 Million	-0.067x	-151.96%
2016-12-31	₩22.14 Billion ≈ $15.00 Million	₩2.85 Billion ≈ $1.93 Million	0.129x	+279.51%
2015-12-31	₩21.90 Billion ≈ $14.84 Million	₩-1.57 Billion ≈ $-1.06 Million	-0.072x	-199.97%
2014-12-31	₩20.67 Billion ≈ $14.01 Million	₩1.48 Billion ≈ $1.00 Million	0.072x	-36.08%
2012-12-31	₩18.56 Billion ≈ $12.58 Million	₩2.08 Billion ≈ $1.41 Million	0.112x	+157.29%
2011-12-31	₩17.74 Billion ≈ $12.02 Million	₩773.08 Million ≈ $523.90K	0.044x	--

About WooGene B&G Co. Ltd

KQ:018620 Korea Pharmaceuticals

Market Cap

$47.07 Million

₩69.46 Billion KRW

Market Cap Rank

#22205 Global

#1393 in Korea

Share Price

₩2675.00

Change (1 day)

+0.19%

52-Week Range

₩670.00 - ₩3400.00

All Time High

₩6913.04